TL;DR
This paper develops a population pharmacokinetic (PK) model for chloroquine (CQ) in COVID-19 patients by combining data from a clinical study and existing literature. The model suggests that current dosing regimens are likely safe, staying below established toxicity thresholds, and provides a foundation for future PK-pharmacodynamic (PK-PD) studies to optimize CQ treatment for COVID-19.
What Problem Does This Paper Address?
The rapid emergence of COVID-19 necessitated the repurposing of existing drugs, including chloroquine (CQ), for treatment. However, understanding how CQ behaves in the body (its pharmacokinetics) in COVID-19 patients was crucial for determining effective and safe dosing. Traditional PK studies often require extensive blood sampling, which is challenging in a pandemic setting. This paper addresses the gap in knowledge regarding CQ PK in COVID-19 patients, particularly given the limited availability of sparse PK data from a clinical trial and the need to establish safe and potentially optimized dosing regimens. The authors aim to build a robust PK model that can inform clinical practice and future research.
Methods
The study employed a population-based meta-analysis approach to develop a PK model. This involved:
- Clinical Study: A single-center, open-label study was conducted with 50 COVID-19 patients receiving a standard dose of CQ phosphate (500 mg twice daily for 7 days). Sparse blood samples were collected at various time points.
- Literature Data Collection: An extensive search of PubMed and Embase databases was performed to gather existing CQ PK data from published literature. Inclusion criteria focused on studies with human subjects, chloroquine phosphate or chloroquine as the drug, and reported plasma concentration-time profiles.
- Population PK Modeling: A two-compartment model with first-order oral absorption and elimination, incorporating an absorption lag time, was used to describe the CQ concentration-time data. This model structure is a standard approach in PK modeling.
- **$PRIOR Functionality:** To leverage existing knowledge and stabilize the model with sparse data, the $PRIOR functionality in NONMEM was utilized, incorporating information from previous PK studies.
- Covariate Analysis: The influence of covariates (e.g., body weight, laboratory parameters) on CQ PK parameters was investigated. Body weight was identified as a significant covariate for clearance (CL/F) and volume of distribution (V2/F), and an allometric scaling model was applied.
- Model Evaluation: Goodness-of-fit (GOF) plots, prediction-corrected visual predictive checks (pcVPC), and comparisons of observed versus predicted concentrations were used to assess the model's performance.
- Simulation: The final PK model was used to simulate CQ plasma concentrations under five different dosing regimens, including standard antimalarial and COVID-19-specific recommendations.
Datasets
The study utilized two primary sources of data:
- Clinical Trial Data: Sparse PK data from 50 COVID-19 patients who received 500 mg CQ phosphate twice daily for 7 days. This dataset included 315 PK observations.
- Literature Data: Additional CQ PK data extracted from 18 published literature reports. This included aggregate mean concentration-time profiles from various populations (healthy subjects, children, pregnant women, malaria patients) and a total of 220 PK data points.
No new benchmark datasets were introduced; rather, existing data from a clinical trial and the literature were integrated.
Key Insights and Ideas
- Meta-analysis for Sparse Data: The study effectively demonstrates the power of combining sparse clinical data with existing literature data through population PK modeling to overcome limitations in experimental studies, especially during a pandemic.
- CQ Dosing Safety: The simulations suggest that commonly used and recommended CQ dosing regimens for COVID-19 are likely to maintain plasma concentrations below established safety thresholds for cardiotoxicity (400 ng/ml), indicating a generally safe profile.
- Body Weight as a Key Covariate: The identification of body weight as a significant covariate influencing CQ clearance and volume of distribution is important for personalized dosing adjustments.
- Foundation for PK-PD: The developed population PK model provides a crucial tool for future PK-pharmacodynamic (PK-PD) studies, enabling the assessment of the relationship between CQ exposure and its efficacy or toxicity in COVID-19 patients.
Key Results
- A two-compartment PK model with first-order oral absorption and elimination, and an absorption lag time, best described the CQ plasma concentration-time data.
- Key PK parameters estimated include:
- Apparent clearance (CL/F): 33.3 L/h
- Apparent central volume of distribution (V2/F): 3630 L
- Absorption rate (ka): 0.559 h⁻¹
- Absorption lag time (ALAG): 0.149 h
- Body weight was incorporated as a covariate, with a fixed allometric coefficient of 0.75 for CL/F and 1 for V2/F.
- Simulations showed that plasma CQ concentrations for most tested dosing regimens remained below the 400 ng/ml safety margin. Regimen 2 showed some concentrations exceeding 400 ng/ml but remaining below 800 ng/ml.
- The model diagnostics (GOF plots, pcVPC) indicated a reasonable agreement between observed and model-predicted concentrations.
Limitations and Future Work
- Limited Covariate Data: The authors acknowledge that due to the limited number of patients, concentrations, and covariate data in the COVID-19 cohort, it might be difficult to identify all significant covariate effects.
- Gene Polymorphism: The influence of gene polymorphisms (e.g., CYP2C8) on CQ metabolism was not evaluated due to data unavailability.
- In-vitro vs. In-vivo Concentrations: The comparison of in-vitro EC50 values with in-vivo plasma concentrations is complex, as it doesn't account for free drug concentrations or tissue distribution.
- Future Work: The paper emphasizes the need for future PK/PD analysis using various biomarkers and clinical endpoints to define the in-vivo effective concentration of CQ for COVID-19 treatment. The developed population PK model is intended to facilitate this assessment, particularly for evaluating CQ alone or in combination therapies.
Summary updated